Adaptive Biotech

Life Sciences Tools and Services

Stránky společnosti

Ticker

ADPT.NASDAQ

Trh

Potenciál růstu

93%

Uzávěrka

6/26/2019

Datum IPO

6/26/2019

Cena umístění

$22

Otevírací cena

$38

Ziskovost

61.27%

O společnosti

Total Funding

$406.9М

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

It was founded in 2009 and headquartered in Seattle, Washington.